GlobeNewswire

Zageno Surpasses its Growth Targets in First Half of 2018; Adds Resources and Structures to Accelerate Growth for the Rest of the Year

Dela

New Hires Include VP, Finance Johann du Toit and VP, U.S. Sales Rafael Casiano ·Headquarters Moves to Cambridge, Mass. USA

CAMBRIDGE, Mass. USA and BERLIN, Germany, June 27, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., an online biotech marketplace, has quadrupled sales in the first half of 2018, exceeding its planned growth trajectory for the year. Chief Executive Officer David Pumberger, Ph.D., attributing success to date to the company's customer-centric culture, announces plans to accelerate growth in the second half of the year. These include: an expanded leadership team comprising key hires in critical positions, bolstered processes and operations so Zageno can extend its high level of responsiveness to an ever-growing list of customer and vendor partners, and a headquarter move to Cambridge, Massachusetts.

"It may sound trite, but we really care about our customers, and it shows," said Pumberger. "Ask them what made them try Zageno for the very first time and there's a good chance they can't tell you: 'Hmm.I saw magnets with the Zageno name everywhere? I heard about it from a friend? To tell you the truth, I can't remember.'

"But if you ask about their experience, their answer is some variation of this: 'I love Zageno's people. I use the chat function or talk to a real person on the phone. And even when I'm not particularly happy because something's not going my way - they work hard to find a quick resolution. It's always a pleasant interaction - and that's so unusual today.'"

Pumberger added, "It may seem counterintuitive for what's, in theory, a 'virtual' company, but one of the founding principles behind Zageno is that close interpersonal connection we develop with our customers to help them succeed. We are committed to building this as we grow, which is why we decided to move our headquarters to the biotech hub of Cambridge - home to many of our key stakeholders: major U.S. academic research institutions, pharma and biotech companies and vendors, and life-science startups.

"It's why we've been adding experienced scientists across the spectrum of research to our customer-service group, and why we are expanding our leadership team." The founders' hiring goal, according to Pumberger: bring in individuals with the experience, skills, and demonstrated track record the company needs so it can delight existing and new customers and vendor partners with even better product offerings and services - while positioning Zageno for accelerated growth and the company's next stage of development.

Johann du Toit and Rafael Casiano will provide the backbone of the company's enhanced administrative and commercial structure as vice presidents of finance and U.S. sales, respectively.

With increased revenues, expanded vendor contracts, and plans for securing additional capital in the company's future, Zageno is formalizing key aspects of its operations. Johann du Toit will be joining Zageno August 1st, bringing a broad range of global finance experience to his charge of building the company's finance function with a modernized approach to facilitating international payment flows, cost control, and more transparency to internal and external stakeholders. He has well-rounded leadership experience, managing projects at Ernst & Young, KPMG, and IKB Deutsche Industriebank, where his mastery of financial modeling proved to be indispensable for his clients' strategy decisions. Most recently, du Toit has taken on interim CFO roles to help several small to medium enterprises to raise funds and streamline their finance functions, among other critical tasks for companies on a rapid growth trajectory. He is a chartered accountant [CA/(SA)], and holds an executive master's in business administration (EMBA) from IE Business School, specializing in entrepreneurship, and a bachelor's degree in finance, accounting, tax, and auditing from the University of Pretoria in South Africa.

Zageno will develop repeatable sales processes under the leadership of Rafael Casiano, who joined Zageno in May. He began his career in the laboratory as a microbiologist at the Florida Department of Agriculture and subsequently led the QC lab for Pall Corporation, where he transitioned to a key account manager position and found his passion in sales and business development. For more than 20 years, Casiano approached his commercial roles successfully as a tenacious customer advocate, amassing deep relationships throughout pharmaceutical, biotechnology, and academic markets. As a global commercial leader at GE Healthcare, he developed commercial processes, combining sales and project-management disciplines to help advance cancer biomarker discovery. He holds a bachelor's degree in microbiology from the University of South Florida.

Chief Revenue Officer Florian Wegener, M.D., Ph.D., M.B.A., commented, "I'm excited to bring in new leadership who will enhance our company culture. We want customers to be able to remember their first personal interaction with Zageno and to tell their colleagues that we were right beside them when we simplified their administrative tasks, integrated into their existing processes, saving them time and money - resolving issues and needs they didn't even know they had."   

About Zageno Inc. ( www.zageno.com ;  twitter:  @ZAGENOteam )

Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions' procurement offices with leading life-science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising about five million products. What do we do? 1) We make purchasing transactions more efficient for both buyers and sellers. 2) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 3) We provide a valuable, expanded sales channel for our vendor partners. The growing Zageno team of 60 in Cambridge, USA, and Berlin, Germany, includes accessible experts in science, e-commerce, systems integration, and customer support. Our people work directly with customers to enable smarter, faster processes - allowing more time and resources for value-added science and better research results. 

Attachment

Caroline Grossman, Communications & Public Affairs, Mirepoix LLC

ZAGENO, Inc.

(781) 771-5579

caroline@mirepoixllc.com

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum